Table 1.
Clinicopathological and molecular data
| Number of cases | Percentage of cases (%) | |
|---|---|---|
| Median age (range) | ||
| 69.7 (36.7–94.0) | ||
| pT stage | ||
| 1a/1b | 101 | 71.1 |
| 2 | 24 | 16.9 |
| 3 | 16 | 11.3 |
| N/A | 1 | 0.7 |
| pN stage | ||
| 0 | 132 | 93.0 |
| 1 | 10 | 7.0 |
| M stage | ||
| 0 | 135 | 95.1 |
| 1 | 7 | 4.9 |
| FIGO Stage | ||
| Ia/Ib | 100 | 70.4 |
| II | 19 | 13.4 |
| III | 16 | 11.3 |
| IV | 7 | 4.9 |
| Grading | ||
| 1 | 45 | 31.7 |
| 2 | 45 | 31.7 |
| 3 | 52 | 36.6 |
| p53 status | ||
| p53 mutation | 20 | 14.1 |
| p53 wildtype | 122 | 85.9 |
| Microsatellite status | ||
| MSS | 93 | 65.5 |
| MSI (MLH1/PMS2) | 42 | 29.6 |
| MSI (MSH2/MSH6) | 7 | 4.9 |
| POLE status | ||
| POLE mutation | 7 | 4.9 |
| POLE wildtype | 135 | 95.1 |
| Molecular Classification | ||
| POLE-mutant | 7 | 4.9 |
| MSI | 47 | 33.1 |
| P53-mutant | 12 | 8.5 |
| NSMP | 76 | 53.5 |